Robert A. Figlin, MD, on Adverse Effects of Cabozantinib in RCC

Video

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Robert A. Figlin, MD, professor of Biomedical Sciences and Medicine, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer, to discuss the adverse effects (AEs) associated with the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) in patients with renal cell carcinoma. Some of the AEs associated with treatment include hypertension and hand foot syndrome, both of which have been well described in the

Transcript:

Clearly, cabozantinib is a drug that has a series of well-described adverse [effects]. It causes hypertension, hand foot syndrome, fatigue, and [gastrointestinal] toxicity. These are all the kinds of toxicities that doctors expect from TKIs. All of these require a multidisciplinary approach and joint management with the nursing staff, but nothing unusual came out in light of that.

Reference

Tannir NM, Agarwal N, Porta C, et al. CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. J Clin Oncol. 2021;39(suppl 15):4501. doi:10.1200/JCO.2021.39.15_suppl.4501

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content